Antoaneta Tsvetkova
Medical University – Varna, BulgariaTitle: New approaches in the treatment of type 2 diabetes - transition from glucose-centred to patient-centred model
Abstract
The high prevalence of Type 2 diabetes mellitus (T2D) all over the
world cause a high demand of searching for new antidiabetic drugs. The present
study aims to identify the consumption of three new classes of antidiabetic
drugs (DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors),
analyzing the use of these drugs prescribed for the treatment of T2D. In this
retrospective observational study, we analyzed consumption data for the period
2015–2020, obtained from National Health Insurance Fund (NHIF) database only.
The NHIF expenditure of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2
inhibitors in Bulgaria for the period 2015-2020 is increasing. The concept of “precision medicine” of the
P4 Medicine approach (Predictive, Preventive, Personalized & Participatory)
outlines new guidelines for the choice of T2D treatment. The management of T2D
is a complex one, where the choice of treatment is patient-centred and focused
on the patient’s needs and comorbidities. The treatment objectives are the optimization
of glycaemic control along with body weight reduction, as well as management of
microvascular or macrovascular complications, and lifestyle changes leading to
an improvement in “quality of life”. The choice of pharmacotherapy needs to
consider the presence of risk factors: risk of hypoglycaemia, cardiovascular
disease (CVD), heart failure (HF), chronic kidney disease (CKD),
contraindications and price. Although last introduced
into clinical practice, SGLT-2 inhibitors were preferred by clinicians, over
GLP-1 agonists, during the considered period.
Biography
Prof. Antoaneta Tsvetkova has completed her Master's degree in
"Health Technology Assessment with Pharmacoeconomics", Professional
Direction of Pharmacy, Faculty of Pharmacy of Medical University – Sofia,
Bulgaria. She is Master of Health Management, Medical University – Varna,
Bulgaria. She is the director of Medical
College, Medical University "Prof. Dr. Paraskev Stoyanov" – Varna,
Bulgaria. Her main professional and scientific interests lie in the fields of
pharmacoeconomics, health technology assessment, pharmaceutical marketing,
public health. She is a member of: WHO European Regions for Health Network
(RHN), BSSPH (Bulgarian Scientific Society of Public Health), Bulgarian Society
for Pharmacoeconomics (ISPOR Bulgaria Chapter), Bulgarian Society of
Obstructive Sleep Apnea and Snoring, Bulgarian Academy of Sleep Medicine,
working committees on health technology assessment at the National Center for
Public Health and Analysis (NCPHA), the General Meeting of the Shareholders of
MHAT "St. Anna – Varna" AD as a representative of the Municipality of
Varna, Standing and Temporary Committees – Standing Committee (SC) on
Healthcare, SC Science and Education, Temporary Committee on Protection and
Reproduction of the Environment at the Municipal Council of Varna, the Advisory
Council for HIV/AIDS Prevention. She has more than 80 publications in
scientific journals and collections of Bulgarian and international conferences.
Co-author of three textbooks related to her teaching activities.
Organization Location
#1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Drop us an email for Program enquiry
diabetes@scientexevents.com
General Queries
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
diabetes@scientexconferences.com
Our Social Presence
Call us at
USA :(+1) 307 464 7366